Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BCMA-CD19 cCAR in Relapsed and /or Refractory Multiple Myeloma and Plasmacytoid Lymphoma

NCT04162353 is registered in ClinicalTrials.gov with iCell Gene Therapeutics as lead sponsor.

NCT NCT04162353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04162353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BCMA-CD19 cCAR in Relapsed and /or Refractory Multiple Myeloma and Plasmacytoid Lymphoma
Lead sponsor
iCell Gene Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
July 1, 2019
Completion date
July 31, 2026
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse, plasmacytoid; lymphoma, refractory multiple myeloma